- Conditions
- Primary Glioblastoma
- Interventions
- 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2, 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2
- Combination Product
- Lead sponsor
- Hemerion Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 1,666
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Drug Effect
- Interventions
- High Morphine Dose, Low Morphine Dose
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- HEC585
- Drug
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Influenza Immunization, Healthy Volunteers
- Interventions
- Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 84 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Bardstown, Kentucky • Salt Lake City, Utah
- Conditions
- Devic's Disease
- Interventions
- Hematopoietic Stem Cell Transplantation, Cyclophosphamide, G-CSF, rATG, Mesna, Rituximab, Methylprednisolone
- Procedure · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Intracerebral Hemorrhage
- Interventions
- Deferoxamine, Normal saline
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Palo Alto, California • San Francisco, California + 19 more
- Conditions
- Norovirus Gastroenteritis
- Interventions
- VXA-G1.1-NN (high dose) Oral Vaccine Tablet, VXA Placebo Tablets, VXA-G1.1-NN (low dose) Oral Vaccine Tablet
- Biological · Other
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Cytopenia
- Interventions
- Emapalumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%
- Drug
- Lead sponsor
- Vistakon Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 5
- States / cities
- Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more
- Conditions
- Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma
- Interventions
- DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide, Doxorubicin, Vincristine, Rituximab, Cyclophosphamide, Prednisone, G-CSF
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ulcerative Colitis, Crohn's Disease
- Interventions
- Vedolizumab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 27
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 22 more
- Conditions
- Peripheral Arterial Disease
- Interventions
- Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA)
- Drug · Behavioral · Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Shock
- Interventions
- Ascorbic Acid, Ringers Lactate or Normal Saline
- Drug · Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Diabetes Mellitus
- Interventions
- IDegLira, Insulin Degludec (U-100), Insulin Aspart
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Healthy Volunteers
- Interventions
- Danavorexton, Danavorexton Placebo, Propofol, Sevoflurane
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- High Tone Pelvic Floor Dysfunction
- Interventions
- Cyclobenzaprine, Pelvic floor massage wand, Pelvic floor physical therapy
- Drug · Device · Procedure
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Traumatic Brain Injury
- Interventions
- Sildenafil Citrate 50Mg Tab, functional Near-infrared Spectroscopy (fNIRS), Carbon Dioxide (CO2) 5%, Neuropsychological Assessments, Gadolinium contrast infusion, Blood sample collection for research purposes, Structural brain Magnetic Resonance Imaging (MRI
- Drug · Device · Other + 1 more
- Lead sponsor
- Uniformed Services University of the Health Sciences
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma
- Interventions
- Encorafenib, Binimetinib, Research Bloods, Tumor Tissue
- Drug · Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Winston-Salem, North Carolina
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
- Interventions
- VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab, Defactinib, Midazolam, Repaglinide
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 616 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more
- Conditions
- Prostate Cancer
- Interventions
- Radiation, Radiation SBRT only, ADT
- Radiation · Drug
- Lead sponsor
- Canadian Cancer Trials Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 710 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 46
- States / cities
- Antioch, California • Dublin, California • Fremont, California + 33 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- efpeglenatide (SAR439977), placebo
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Canoga Park, California + 26 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- ADZENYS XR-ODT, Placebo Oral Tablet
- Drug
- Lead sponsor
- Aytu BioPharma, Inc.
- Industry
- Eligibility
- 4 Years to 5 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Status Asthmaticus
- Interventions
- Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC), Airlife Sidestream High Efficiency Nebulizer
- Device
- Lead sponsor
- Akron Children's Hospital
- Other
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Akron, Ohio
- Conditions
- Hookworm Infection, Hookworm Disease
- Interventions
- Na-GST-1/Alhydrogel®, CpG 10104
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia